This is a preview of subscription content, log in via an institution to check access.
Notes
National Cancer Institute of Canada Clinical Trials Group
The study was supported in part by Pfizer Pharmaceuticals.
Reference
Maunsell E, et al. Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer. Journal of Clinical Oncology 32: [12 pages], 7 Apr 2014. Available from: URL: http://doi.org/10.1200/JCO.2013.51.2483
Rights and permissions
About this article
Cite this article
Exemestane for breast cancer prevention: low QOL impact. PharmacoEcon Outcomes News 703, 9 (2014). https://doi.org/10.1007/s40274-014-1267-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1267-3